Pediatric Cardiology

, Volume 24, Issue 4, pp 338–343

Dobutamine Stress Echocardiography in the Evaluation of Young Patients with Kawasaki Disease

Authors

    • Non-invasive Cardiac Imaging and Hemodynamic Research LaboratoryCincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, C-4, Cincinnati, OH, 45229-3039
  • G. Goya
    • Non-invasive Cardiac Imaging and Hemodynamic Research LaboratoryCincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, C-4, Cincinnati, OH, 45229-3039
  • S. A. Witt
    • Non-invasive Cardiac Imaging and Hemodynamic Research LaboratoryCincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, C-4, Cincinnati, OH, 45229-3039
  • B. Glascock
    • Non-invasive Cardiac Imaging and Hemodynamic Research LaboratoryCincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, C-4, Cincinnati, OH, 45229-3039
  • T. R. Kimball
    • Non-invasive Cardiac Imaging and Hemodynamic Research LaboratoryCincinnati Children’s Hospital Medical Center, 3333 Burnet Avenue, C-4, Cincinnati, OH, 45229-3039
Original Article

DOI: 10.1007/s00246-002-0327-9

Cite this article as:
Zilberman, M., Goya, G., Witt, S. et al. Pediatr Cardiol (2003) 24: 338. doi:10.1007/s00246-002-0327-9

Abstract

There has been no consistent approach to the follow-up of Kawasaki disease patients for remote coronary perfusion abnormalities. Dobutamine stress echocardiography (DSE) has become a standard method for evaluation of perfusion abnormalities in adults with coronary artery disease. In addition, DSE has been used with success in some pediatric patients. The purposes of this study were to evaluate safety and accuracy of DSE in the follow-up of patients with Kawasaki disease, to evaluate whether DSE adds any additional value to the resting echocardiogram, and to determine the association of DSE results with American Heart Association (AHA) risk level categories. DSE was performed 1 month to 13 years after acute Kawasaki disease in 47 patients (range, 3.8–22.6 years; 33 males and 16 females). Patients were stratified according to AHA risk level categories (I–V). Ischemia was defined as a new or worsening regional wall motion abnormality or >1 mm ST segment depression on the electrocardiogram during DSE. In 45/47 patients, DSE was completed successfully (i.e., achievement of target heart rate or development of ischemia). No patients in risk levels lower than V (i.e., patients without coronary artery stenoses) had positive DSE, whereas 2/4 (50%) in the risk level V category had positive DSE, both of whom had coronary occlusion >50% confirmed by angiography. Of the 2 AHA risk level V patients with negative DSE, 1 had extensive collateralization and the other had coronary obstruction <50%. DSE is a safe and feasible method for the evaluation of children with Kawasaki disease. DSE provides a confirmatory benefit and may be a useful screening alternative to cardiac catheterization during follow-up. Patients in AHA risk levels I–IV are unlikely to have dobutamine-induced coronary perfusion abnormalities. Patients in the risk level V category may or may not have positive DSE depending on the degree of both coronary obstruction and collateralization.

Keywords

Dobutamine stress echocardiographyKawasaki disease

Copyright information

© Springer-Verlag 2003